Diabetes linked to worse disability in MSWhen multiple sclerosis patients also have comorbid diabetes, their disability scores tend to be greater than those of MS patients who do not have the disease. Safinamide disappoints in preventing dyskinesia in Parkinson's patientsThe new drug safinamide might have some impact in preventing the involuntary movements characteristic of Parkinson's disease. However, it did not perform any better than placebo over a two-year period. Regional riddle emerges from epilepsy drug study New treatment is effective in Canada and U.S., but not in rest of North America; epilepsy classification may have been a factor Canadian MS clinics see results with natalizumab Real-world outcomes with investigational drug still favourable Train the brain to ward off dementia Course improves memory by recruiting healthy tissue Device uses submarine technology to diagnose stroke quickly Prototype is portable, easy to use Evidence lacking for Alzheimer’s drug in mild cases Sunlight, vitamin D linked to lower MS risk Research from Australia—which has the highest skin cancer rate in the world—suggests sun exposure also can be viewed in a sort of positive light: It may reduce the risk for developing multiple sclerosis. A window into the body Gilenya: new MS drug approved by Health Canada Health Canada approves first disease-modifying oral treatment for multiple sclerosis in Canada. First Previous 47 48 49 50 51 Next Last
